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Abstract
Background: Individuals with HIV have a high prevalence of physical and psychological symptoms throughout
their disease course. Despite the clinical and public health implications of unresolved pain and symptoms, little is
known about the effect of anti-retroviral therapy (ART) on these outcomes. This study aimed to assess the impact
on symptom burden for the year after ART initiation in individuals with a CD4 count <200 cells/uL in Uganda.
Methods: HIV-infected, ART-naıve adults referred from voluntary testing and counseling services in rural
Uganda for enrollment into a randomized controlled trial to test fluconazole as primary prophylaxis against
cryptococcal disease were invited to complete the Memorial Symptom Assessment Scale-Short Form
(MSAS-SF) prior to commencing ART and at two subsequent follow up visits. This tool measures self-reported
7-day period prevalence and associated burden of physical and psychological symptoms. Changes in the total
number of symptoms and distress indices with time on ART and trial arm were investigated through fitting
Linear Mixed Models for repeated measures.
Results: During the first year of ART initiation the prevalence of most individual symptoms remained
constant. The notable exceptions which improved after commencing ART are as follow; prevalence of pain
(prevalence changed from 79% to 60%), weight loss (67% to 31%), lack of appetite (46% to 28%), feeling sad
(52% to 25%) and difficulty sleeping (35% to 23%). The total number of symptoms and distress indices
reduced after treatment commenced. Of concern was that half or more study participants remained with
symptoms of pain (60%), itching (57%), skin changes (53%) and numbness in hands and feet (52%) after
starting ART. Sixteen symptoms remained with a burden of 25% or more.
Conclusion: Despite the beneficial effect of ART on reducing symptoms, some patients continue to
experience a high symptom burden. It is essential that HIV services in sub-Saharan Africa integrate
management of symptoms into their programmes.
Trial registration: CRYPTOPRO [ISRCTN 76481529], November 2004.
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Background
An estimated 36.7 million individuals in Sub-Saharan
Africa are infected with HIV [1]. The rapid roll-out of
anti-retroviral therapy (ART) has led to a treatment
coverage of approximately 50% [1]. ART suppresses viral
replication, restores immune function and has led to sig-
nificant reductions in morbidity and improved survival.
Where treatment is available, HIV infection is transition-
ing into a chronic disease. A high prevalence of trouble-
some symptoms is reported at all stages of HIV infection
and persists during treatment [2–5]; if identified, these
symptoms can be successfully controlled [6]. Growing
evidence suggests that unpleasant symptoms are associ-
ated with poor treatment adherence [7], unprotected
sexual intercourse [8], HIV viral load rebound [9], and
reduced quality of life [10] potentially influencing HIV
transmission [7, 11]. Furthermore, HIV positive people
receiving ART report a higher prevalence of mental
health illness [5] and perceived stigma than the general
population [12]. Therefore, managing physical and psy-
chological symptoms through palliation becomes a
major challenge in HIV care.
We have previously published evidence of a high
prevalence and burden of physical and psychological
symptoms among individuals in Uganda who were eli-
gible to begin receiving ART but had not yet started
ART [4]. Studies that have investigated longitudinal
changes in global quality of life of people taking ART in
sub-Saharan Africa suggest improvements in some mea-
sured outcomes [13–15]. Individuals with HIV may have
multiple physical and psychological symptoms and a de-
tailed assessment and management of illness burden is a
vital part of quality of life assessment. However, to date
there has been a paucity of longitudinal reports describ-
ing detailed clinical symptomatology as an outcome for
HIV-infected individuals in sub-Saharan Africa accessing
treatment. This study aimed to measure longitudinal
symptom burden from before commencing ART and
during the first year of treatment in a population of
adults with a CD4 count <200 cells /uL in Uganda.
Methods
Setting
The Symptom Burden Longitudinal Cohort Study was
conducted in a rural district in South Western Uganda.
It was conducted within a double-blind randomised pla-
cebo controlled trial which determined that primary
prophylaxis with fluconazole reduced morbidity and
mortality from invasive cryptococcal disease in HIV in-
fected Ugandan adults [16]. ART-naive adults were re-
ferred to the CRYPTOPRO study clinic following
voluntary testing and counselling at one of the five local
HIV care and treatment organisations.
Study population
In line with the selection criteria of the main study,
study subjects comprised consenting ART-naive adults,
with laboratory confirmation of HIV, CD4 count <200
cells/uL, and a negative cryptococcal antigen test. Exclu-
sion criteria included pregnancy and liver function tests
greater than three times the upper limit of normal [16].
Participants received either 200 mg of fluconazole or an
identical placebo (Cipla, India) three times per week
from the baseline enrolment visit until the end of the
trial (minimum 12 weeks) or until their CD4 count
reached 200 cells/μl.
Antiretroviral therapy
Local ART providers managed initiating ART independ-
ently of the CRYPTOPRO trial team and chose the drug
combination and monitored antiretroviral regimens (two
nucleoside reverse transcriptase inhibitors and one non-
nucleoside reverse transcriptase inhibitor). Patients were
offered routine co-trimoxazole prophylaxis (960 mg three
times a week) according to standard Ugandan guidelines.
Symptom burden procedure and tools
All ART-naïve participants enrolling in CRYPTOPRO
on one randomly chosen day per week between 2007
and 2008 were invited to complete the Memorial Symp-
tom Assessment Scale-Short Form (MSAS-SF) [17] with
a trained counsellor. The MSAS-SF was translated into
local languages, back-translated, and administered to cli-
ents in the language of their choice (available as Add-
itional file 1) . The MSAS-SF was then repeated at either
one or two follow-up visits after commencing ART over
a one-year period. MSAS-SF is a patient-rated symptom
measurement tool, which records the seven-day period
prevalence and associated burden of 28 physical and
four psychological symptoms. For each symptom the re-
spondent indicated whether or not they have experi-
enced it in the previous 7 days. For those symptoms
experienced, each is then scored according to perceived
burden. A burden score is allocated to each prevalent
physical symptom depending on the level of discomfort
reported (not at all = 0.8, a little = 1.6, somewhat = 2.4,
quite a bit = 3.2, very much = 4). Similarly, a score is al-
located to each prevalent psychological symptom de-
pending on the frequency (rarely = 1, occasionally = 2,
frequently = 3, almost constantly = 4). For any symptom
(either physical or psychological) that is not experienced,
a burden score of zero is allocated. Each MSAS-SF sub-
scale is then calculated from the mean burden score for
a pre-defined subset of the items. The Global Distress
Index (GDI) is based on 10 parameters; six physical
symptoms (pain, lack of energy, lack of appetite, dry
mouth, drowsiness and constipation) and four psycho-
logical factors (feeling sad, worried, irritated and
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nervous). The Physical Symptom Distress Score (PHYS)
is based on 12 physical symptoms (pain, lack of energy,
lack of appetite, feeling drowsy, constipation, dry mouth,
nausea, vomiting, change in taste, weight loss, feeling
bloated and dizziness). The Psychological Symptom Dis-
tress Score (PSYCH) is based on burden of six psycho-
logical symptoms (feeling sad, worried, nervous,
difficulty sleeping, feeling irritable and difficulty concen-
trating). Significant symptom distress is suggested by a
MSAS-SF subscales scores greater than one. A pilot
study of MSAS-SF in Uganda (personal communication,
Dr. K. Frame) identified a further nine prevalent physical
symptoms (hunger, difficulty moving, difficulty walking,
muscle aches, poor vision, poor hearing, sore lumps on
private parts, discharge from private parts and bad
smell/body odour,) and these were added to our ques-
tionnaire, as described previously [4].
Statistical analysis
Data from hand-annotated symptom burden question-
naire were entered into a database created in MS-
ACCESS and patient data was extracted from the main
CRYPTOPRO study database. The prevalence of each
symptom was tabulated to allow comparison between
the pre- and post-ART visits. Individual physical symp-
tom burden reported as “quite a bit” or “very much” was
regarded as experiencing “high distress”. Similarly, indi-
viduals who reported a psychological symptom causing
distress “frequently” or “constantly” were regarded as ex-
periencing “high frequency” distress. The three subscale
symptom distress indices (GDI, PHYS and PSYCH) were
calculated from the mean burden scores. Changes in
subscale symptom distress indices with time on ART
was assessed by fitting Linear Mixed Models (LMMs)
for repeated measurements [18, 19] to investigate
whether, and if so, how, the total symptom score, the
global distress index, the physical symptom score and
the psychological symptom score changed with time on
ART. Scores recorded before initiation of ART were as-
sumed to be at time zero, for other observations time
was number of days on ART. Regression analyses carried
out on the scales at baseline suggested the use of a
square root transformation of the outcome in order to
satisfy the assumption of homogeneity of variance. Thus
the square-root of each scale was used as the outcome
variable, which also ensured that predicted values from
the model would always be positive after back-
transformation to the original scale. In addition, the
models investigated whether there was evidence of non-
linearity of the effect of time on ART; the models were
fitted using Maximum Likelihood Estimation (MLE) ra-
ther than the more conventional Residual Maximum
Likelihood Estimation (REML) in order to assess extra
fixed effect terms in the model. A quadratic term in days
post-ART was added if it significantly increased the
model deviance (minus twice the log-likelihood) at the
5% level; the square root of days since ART was used in-
stead of a quadratic model if it resulted in a lower re-
sidual deviance than the quadratic model. The number
of days post-ART was scaled by dividing by 100 to give
greater numerical stability.
Further linear mixed models were fitted to investigate
whether the total number of symptoms and the symptom
scores were associated with either the ART regimen or the
CRYPTOPRO treatment arm (fluconazole vs. placebo),
adjusting for CD4 cell count and length of time on ART.
All analyses were carried out using Stata release 11.2
(College Station, TX).
Ethics
This study received ethical approval from the Uganda
Virus Research Institute and Uganda National Council
for Science and Technology.
Results
Study participant characteristics
From the cohort the MSAS-SF was completed by 97
participants at study baseline before and after initiating
Table 1 Study participants characteristics (n = 97)
Factor n (%)
Sex Male 30 (31%)
Female 67 (69%)
Age Mean (s.d.) 36 (8)
WHO HIV stage 1 3 (3%)
2 34 (35%)
3 54 (56%)
4 6 (6%)
CD4 cells (cells/ul) <50 22 (23%)
50–99 19 (19%)
100–149 24 (25%)
150–199 32 (33%)
Main study
treatment arm
Median
(IQR)
120 (58–
163)
Fluconazole 47 (48%)
Placebo 50 (52%)
Anti-retroviral treatment backbone
(missing = 2)
AZT/3TC 77 (81%)
D4T/3TC 16 (17%)
Truvada 2 (2%)
Non-nucleoside reverse-transcriptase inhibitors
(missing = 1)
Nevirapine 70 (73%)
Efavirenz 26 (27%)
Died during study No 88 (91%)
Yes 9 (9%)
AZT zidovudine; 3TC lamivudine; d4T Stavudine; Truvada emtricitabine and
tenofovir disoproxil fumarate
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ART (Table 1). The median length of time on ART was
300 days (IQR 140–377). Individuals completed two or
three data points after initiating ART.
Seven-day period prevalence of symptoms and symptom
distress indices
The prevalence of pain, weight loss, lack of appetite,
feeling sad, difficulty sleeping and walking, problems
urinating, irritability, feeling nervous and mouth sores
reduced in frequency during the early phases of taking
ART (Table 2). In cases where individuals had more than
one follow-up visit while on ART, the symptom burden
at the longest time on ART has been used. The
remaining 31 symptoms remained at a similar burden
with 16 persistent symptoms having a frequency of over
25%. While the prevalence of pain reduced from 79 to
60% on commencing ART, the burden remains high and
of those with pain, 25% reported high distress associated
with this symptom. Of concern is that half or more
study participants remained with symptoms of itching
(%), skin changes (%) and numbness (%) after starting
ART. A high prevalence of distress at follow-up was re-
ported for sexual activity (36%), hunger (34%), changes
to skin (27%), pain (25%), numbness and tingling (22%),
feeling sad (21%) and worry (21%) (Table 2). New symp-
toms after initiating ART were particularly prevalent for
hunger (26%), problems with sexual activity (25%) and
cough (20%) (Table 2).
The proportions of participants experiencing numb-
ness or tingling after starting ART were similar for those
on an AZT based regimen (51%) and those on a d4T-
based regimen (56%). The prevalence of symptoms that
could potentially be altered by the trial drug fluconazole,
namely pain, weight loss, lack of appetite, sore or dis-
charging private parts, difficult swallowing and mouth
sores did not differ between those on the active drug
and the placebo in this study.
Changes in subscale symptom distress indices with time
on ART
The mean total number of symptoms decreased after
commencing ART from 12.8 (11.7–13.9) to 7.8 (6.8–8.9)
(p = <0.0001) (Table 3). The summary scores for GDI,
PHYS and PSYCH all approximately halved after starting
ART (Table 3). The change in the total number of symp-
toms and the three indices with time on ART were in-
vestigated through fitting LMMs for repeated measures;
the number of symptoms and each index was subject to
a square-root transformation to meet the assumption of
homogeneity of variance (Table 4, Fig. 1).
The model for square-root of the number of symp-
toms included terms in days post ART and days-
squared, leading to the fitted equation for the predicted
number of symptoms as follows: SYMPTOM-
fit = (0.164*(days/100)2–0.942*days/100 + 3.51)2.
The model for the square root of the Global Distress
Index included a term for the square-root of the number
of days post ART, leading to the following equation to
predict the GDI as follows: GDIfit = (1.07–0.316 *
√(days/100))2.
The model for the square root of the Physical Symp-
tom Score included terms for day and day-squared, lead-
ing to the following equation: PHYSfit = (0.077*(days/
100)2–0.402*days/100 + .951)2.
The model for the square root of the Psychological
Symptom Score included a term for the square-root of
the number of days post ART, leading to the following
equation to predict the score as follows: PSY-
CHfit = (0.820–0.268 * √(days/100))2.
The fitted curve shows that the expected total number
of symptoms declines from an initial value of 12.3 at day
0 down to 0.43 at 300 days. The decline is initially fairly
rapid and then slows down (Fig. 1). The graph also
shows the great variation between subjects; initially
some individuals experience more than 25 symptoms,
however after about 100 days no one has more than 20
symptoms and after about 200 days, no one has more
than 10 symptoms.
The graph of observed and predicted GDI against days
on ART shows that the expected GDI drops from an initial
value of 1.15 to 0.27 by day 300 (Fig. 1). The initial drop
in total number of symptoms is relatively quick and it then
levels off. The graph of physical symptom scores against
days on ART shows that the expected physical symptom
score drops from an initial value of 0.90 to 0.19 by day
300. There is however a great deal of variability in this
score and some participants still have scores close to 1 to-
wards day 300. As the number of days on ART increases,
the psychological symptom expected score drops from an
initial value of 0.67 to 0.13 by day 300.
There was no association found between total number
of symptoms or the symptom distress indices and ART
regimen, CRYPTOPRO treatment arm (fluconazole vs.
placebo) or CD4 cell count.
Discussion
This longitudinal study of symptom burden during the
first year of ART treatment shows that while ART re-
duces symptom profile in HIV infected individuals, cer-
tain symptoms retain a high burden. Of particular
concern is the high burden and high distress associated
with the top 10 most prevalent symptoms despite com-
mencing ART caused by pain (60%), itch (57%), skin
changes (53%), numbness and tingling in hand and feet
(52%) and hunger (48%), cough (46%), worry (45%), lack
of energy (43%), problems sexual activity (42%) and
fatigue (41%).
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Table 2 Frequency of symptoms in past week prior to starting ART and frequency, distress and prevalence of new symptoms after
starting ART for 97 study participants
Symptom Burden of symptoms prior to
starting ART [n (%)]
Burden of symptoms after
starting ART [n (%)]
Prevalence of high distress in
participants with symptom
after starting ART [n [%)]
Pain 77 (79%) 58 (60%) 34 (25%)
Itching 69 (69%) 55 (57%) 30(31%)
Changes in skin 49 (51%) 51 (53%) 26 (27%)
Numbness/tingling in the hands/feet 52 (54%) 50 (52%) 21 (22%)
Hunger 47 (43%) 47 (43%) 33 (34%)
Cough 44 (45%) 45 (46%) 14(14%)
Worrying 58 (60%) 44 (45%) 20(21%)
Lack of energy 51 (52%) 42 (43%) 17(18%)
Problems with sexual interest/activity 37 (33%) 41 (42%) 35 (36%)
Feeling drowsy/tired 53 (55%) 40 (41%) 11 (11%)
Weight loss 65 (67%) 30 (31%) 11 (11%)
Lack of appetite 45 (46%) 27 (23%) 16(16%)
Sores or lumps on private parts 22 (29%) 27 (23%) 11 (11%)
Dizziness 38 (39%) 26(27%) 12(12%)
Changes in the way food tastes 30 (31%) 24 (25%) 9 (9%)
Feeling sad 50 (52%) 24 (25%) 20(21%)
Difficulty sleeping 34 (35%) 22 (23%) 12(12%)
Dry mouth 32 (33%) 20 (21%) 5 (5%)
Nausea 20 (21%) 20 (21%) 8 (8%)
Difficulty walking 35 (36%) 19 (20%) 7(7%)
I do not like myself 28 (29%) 18 (19%) 13(13%)
Muscle aches 27 (28%) 18 (19%) 9 (9%)
Difficulty seeing well - poor vision 18 (19%) 17 (18%) 6 (6%)
Constipation 16 (16%) 15 (15%) 7(7%)
Problems urinating 18 (19%) 14 (14%) 5 (5%)
Sweats 29 (30%) 14 (14%) 4 (4%)
Diarrhea 16 (16%) 13 (13%) 7(7%)
Feeling bloated 17 (18%) 13 (13%) 4 (4%)
Difficulty swallowing I5 (16%) 12 (12%) 11 (11%)
Feeling irritable 26 (27%) 11(11%) 2 (2%)
Difficulty concentrating 7 (7%) 10 (10%) 3 (3%)
Difficulty moving 14 (14%) 10 (10%) 2 (2%)
Shortness of breath 16 (17%) 10 (10%) 4 (4%)
Bad smell/odour from body 8(8%) 8(8%) 2 (2%)
Feeling nervous 27 (28%) 8(8%) 4 (4%)
Difficulty hearing well - poor hearing 6 (6%) 7(7%) 2 (2%)
Hair loss 11 (11%) 7(7%) 3 (3%)
Swelling of arms or legs 9 (9%) 7(7%) 3 (3%)
Discharge from private parts 15 (16%) 6(6%) 4 (4%)
Vomiting 8 (8%) 5(5%) 1 (1%)
Mouth sores 19 (20%) 3(3%) 3 (3%)
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In accordance with other studies we found that the
greatest improvement in patient self-reported outcomes
were in the initial months of ART with more modest reduc-
tions after longer periods of therapy [13, 14]. The MSAS-SF
allows collection of extensive information on common
physical and psychological symptoms, giving it the advan-
tage of being a clinically useful tool. Symptom burden and
quality of life instruments that group markers of wellbeing
together enables the comparison of study participants with
other populations with chronic illness and further, allows
quantification of the outcomes of interventions [10]. While
quality of life scores are an important outcome, global indi-
ces do not allow understanding of changes among individ-
ual symptoms. Distressing symptoms may be masked by
improvements in global parameters.
There are notable improvements in the overall burden of
the majority of both prevalent physical and psychological
symptoms, but persistent or residual burden remains in
some areas. About 60% of the participants continued to re-
port pain, with one in five people with this symptom con-
tinuing to experience high distress. The causes of pain in
the setting of HIV illness are multifactorial and it is particu-
larly concerning in a setting with a lack of symptom control
management and access to opioid analgesics. Numbness/
tingling are reported in about half of study participants be-
fore and after commencing ART. Neuropathy is a common
complication of HIV and is associated with advanced im-
munosuppression and low CD4 cell counts [20] and has
been used as a predictor of death in resource limited
settings [21]. In this study about 20% of patients developed
a new symptom of peripheral neuropathy on commencing
ART, but this was not related to the use of stavudine, a drug
associated with neuropathy [22]. It is feasible that symp-
toms of pain and neuropathy could be managed effectively
and at low cost with analgesics. It is of great concern that
there is so little infrastructure available to address the pro-
found symptom burden need [23].
Hunger does not decrease with commencing ART. In
our study population, barriers to eating such as lack of
appetite, nausea, a dry mouth and mouth sores all de-
clined with ART and self-reported weight loss was re-
duced. However, hunger remained common and
reported by about one-half of our participants through-
out our study duration. A recent study conducted in
Tanzania, Uganda and Zambia identified ART related
hunger or not having enough food as a significant con-
tributor to poor ART adherence [24]. ART driving in-
creased appetite has been reported and food insecurity
in poor populations cannot be overlooked. The integra-
tion of food assistance into HIV care programmes im-
proves drug adherence [25].
ART was associated with clinically meaningful im-
provement in psychological symptom burden and feel-
ings of being sad, irritable, and nervous and agreement
with the statement “I do not like myself”. However, the
psychological burden of worry remained in about a half
of adults questioned and was a new symptom in about a
third of patients commencing ART. The reasons behind
these reports of psychological symptom burden were
outside the scope of this study but one could postulate
that, as the HIV infection moves from an acute to a
chronic illness, a patient’s attitude changes as they
realize that they are no longer at risk of an imminent
death. Concerns about the future and pressures to ad-
here to ART, however, may explain the stubborn persist-
ence of worry. A recent study of HIV infected
individuals’ views on HIV treatment reported many
negative psychosocial effects of ART, including a per-
ceived trade-off between longevity and quality of life
with issues surrounding career, finances, relationships
Table 3 Mean number of symptoms and mean symptom
distress indices by visit
All Participants (n = 97)
Index Before starting ART,
mean value [95% Cl)
After starting ART,
mean value [95% Cl)
Total number of symptoms 12.8 (11.7–13.9) 7.8 (6.8–8.9)
Global Distress Index 1.29 (1.1–1.4) 0.7 (0.6–0.8)
Physical Symptom Distress 1.0 (0.9–1.1) 0.5 (0.4–0.6)
Psychological Symptom
Distress
1.0 (0.8–1.2) 0.5 (0.4–0.6)
Table 4 Results for total number of symptoms and symptom distress indices when fitting linear mixed models to transformed
sclaes
Parameter Square root of total
Number of Symptoms
Square root of
Global Distress Score
Square root of Physical
Symptom Distress Score
Square root of Psychological
Symptom Distress Score
Constant 3.5 (3.4; 3.7) 1.1 (1.0; 1.1) 1 (0.9; 1.0) 0.8 (0.7; 0.9)
Days/100 −0.9 (−1.3; −0.6) – −0.4 (−0.5; −0.3) –
(Days/100)2 0.2 (0.04; 0.3) – 0.1 (0.02; 0.1) –
√(Days/100) – −0.3 (−0.4; −0.2) – −0.3 (−0.4; −0.2)
σu (Between subjects) 0.5 (0.4: 0.7) 0.1 (0.06; 0.3) 0.1 (0.1; 0.2) 0.2 (0.2; 0.4)
σe(Within subjects) 0.7 (0.6; 0.8) 0.4 (0.3; 0.4) 0.3 (0.3; 0.4) 0.5 (0.4; 0.5)
Note that each cell contains the parameter estimate together with 95% confidence limits where appropriate (i.e. if the given parameter is included in the model)
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with health care workers, housing security, sexual health
and stigma [26].
The number of symptoms and symptom distress indi-
ces reduced to around half of their original score during
the duration of this study. Improvements in quality of
life subscales, but persistence of a relatively high fre-
quency of specific symptoms after commencing ART is
reported in other studies in sub-Saharan Africa [13–15].
Pitt and colleagues reported that despite a statistically
significant improvement in health quality overall, the
physical health score declined for nearly one quarter of
the subjects and the mental health score declined for
over one third [13]. In another study, the health related
quality of life score for the study population after
12 months of ART had significantly improved, but
nearly one-third of patients still experienced some or se-
vere pain after 12 months of ART [15]. In a study of the
impact of the first 6 months of ART on economic activ-
ity in South Africa [27] ART was associated with less
functional impairment, fewer symptoms and better work
performance. But over one-third continued to have
functional impairment and the frequency of absenteeism,
prevalence of body pain or headaches, fatigue, feeling
unwell and depression all remained high. The reasons
behind the lack of further improvement with ART are
unclear but warrant further investigation; it may repre-
sent residual HIV symptoms, treatment related toxicity
or complex psychosocial stresses. Data on long-term
ART with immunological recovery from Western co-
horts suggests a changing profile but persistent burden
of symptoms [28–30]. The implication of this is that
ART alone is not sufficient to reverse HIV-associated
symptom burden and that clinical support to address
physical and psychological needs will be required during
the entire disease course.
This study highlights the significant impact that ART
can have on improving symptom outcomes during the
first year of initiation, but the enduring physical and psy-
chological burden that remains is sobering. Recognition
of a residual, often high, burden of symptoms is of key im-
portance for clinicians and policy makers. While relief
from pain and suffering is a basic human right [31] and
a b
c d
Fig. 1 Observed values and fitted curves using a linear mixed model with study participants regarded as having random effects for total number of
symptoms (panel a), Global Distress Index (panel b), Physical Symptom Distress Score (panel c) and Psychological Symptom Distress Score (panel d)
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requires no further justification, there are other reasons to
pay attention to and monitor symptoms. Symptoms may
well have a negative impact on ART adherence and risky
behavior and hence HIV transmission. A study reported
psychological symptom burden was significantly and inde-
pendently associated with having unprotected sexual
intercourse, and poor ART drug adherence [11]. Further-
more, physical symptoms including nausea and pain are
known to be barriers to ART adherence [7, 32–34].
We believe that this study could have underrepresented
the burden of symptoms in the population. Recruitment
through a clinical trial with a defined inclusion and exclu-
sion criteria means that participants may have differed in
some ways from other HIV-infected Ugandans. The study
participants were well enough to travel to a health clinic to
be interviewed, and fulfilled strict trial criteria for enrol-
ment. Further, our participants had access to trained med-
ical staff, free diagnostics and treatment throughout the
duration of the study and standard protocols existed for in-
vestigation and treatment of common HIV related condi-
tions. More women were recruited than men, but the
higher female to male ratio is consistent with the gender ra-
tio starting HIV treatment in Uganda [35]. Although this
was a trial population, the immune status of the study
population was broadly representative of individuals at ini-
tial presentation for ART in sub-Saharan African countries
at the current time [36]. We employed a counselor to assist
in completing the questionnaire, although the counselors
were trained this may have potentially introduced bias.
Conclusions
While reductions in symptom burden indices following
commencement of ART are encouraging, a high residual
frequency of symptoms remains. Commencing ART her-
alds the mark of personal acceptance of HIV status. ART
potentially allows individuals to return to work and nor-
mality, and contribute to society. However, the transition
from a fatal illness to a chronic disease is placed at risk if
symptoms are perceived to out-weigh benefits. On-going
symptoms may erode previous improvements in behavior
that reduce HIV transmission if symptom burden leads to
poor ART adherence and attrition from HIV care [37]. It
is essential that symptom control measures are applied
through the disease and treatment trajectory and is valued
for its practical and humanitarian gains.
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